We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
1. Endometrial cancer: integrating molecular insights into personalized care
- Dr. Gemma Eminowicz
-
4. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
5. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
6. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
7. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
8. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
9. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
10. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Comprehensive sickle cell care in the era of gene therapy
- Prof. Sophie Lanzkron
-
17. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
18. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
19. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
20. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
21. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
23. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
24. Hemophilia A
- Dr. Snejana Krassova
-
27. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
28. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
29. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
30. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
32. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
33. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
34. Next-generation RNA vaccines
- Dr. Anna Blakney
-
35. Harnessing the immune system for cancer therapy
- Dr. Raghav Sundar
-
36. Rac-enhanced CAR immunotherapy: RaceCAR
- Prof. Denise Montell
-
37. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 1
- Prof. Kevin Harrington
-
38. Enhancing innate anti-tumour immunity: lessons from virotherapy and STING agonism 2
- Prof. Kevin Harrington
-
39. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
40. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
41. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
42. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
43. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
44. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
45. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
46. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
48. HCV resistance
- Prof. John Dillon
-
49. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
50. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
51. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
52. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
53. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
54. Cow’s milk allergy: the future
- Dr. Carina Venter
-
55. Cow's milk allergy: management
- Dr. Carina Venter
-
56. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
57. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
58. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
59. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
60. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
61. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
62. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
63. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
64. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
65. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
67. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
68. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
69. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
71. Huxley’s science fiction: ion channels in pain, pain resilience, and beyond
- Prof. Stephen Waxman
-
72. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
73. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
74. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
75. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
76. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
77. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
78. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
79. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
80. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
81. Integration of multi-omics data
- Prof. Ana Conesa
-
82. Bone marrow mesenchymal cells 1
- Prof. Arnold I. Caplan
-
83. Bone marrow mesenchymal cells 2
- Prof. Arnold I. Caplan
-
84. Peptide-drug conjugates as therapeutic modality in drug development 1
- Dr. Syed Faheem Askari Rizvi
-
85. Peptide-drug conjugates as therapeutic modality in drug development 2
- Dr. Syed Faheem Askari Rizvi
-
86. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
87. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
88. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
89. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
90. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
91. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
92. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
93. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
94. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
95. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
96. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
97. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
98. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
99. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
100. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
101. Diagnosis of tuberculosis and drug resistant tuberculosis 1
- Dr. Daniela Cirillo
-
102. Diagnosis of tuberculosis and drug resistant tuberculosis 2
- Dr. Daniela Cirillo
-
103. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
104. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
105. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
106. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
107. New drugs for asthma
- Prof. Peter Barnes
-
108. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
109. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
- Archived Lectures *These may not cover the latest advances in the field
-
111. AI and big data in drug discovery
- Mr. Ed Addison
-
112. Molecular brain imaging (PET) in diseases with dementia
- Prof. Emeritus Karl Herholz
Printable Handouts
Navigable Slide Index
- Introduction
- Analysis of multi-omics data
- The road of multi-omics data analysis
- ConesaLab tools
- Challenges in multi-omics integration
- Heterogeneous data properties in multi-omics
- Sample size calculations in multi-omics (1)
- Sample size calculations in multi-omics (2)
- Multi-omics data fusion across experiments
- Multilayered transcriptional regulation
- The STATegra dataset for mouse B-cell differentiation
- MORE: Multi-omics for gene local regulatory networks
- MORE results on STATegra data (B-cell differentiation)
- Multi-layered regulation of glycolysis during B-cell differentiation
- Bipartite regulatory network
- Multilayered metabolic regulation connected to disease
- Modelling longitudinal multi-omics data: TEDDY example
- Data analysis strategy
- Data analysis strategy: Modelling and interpretation
- Statistical modelling with NPLS-DA (1)
- Statistical modelling with NPLS-DA (2)
- Enrichment analysis multi-omics T1D signature
- Mechanistic interpretation with Paintomics
- Multi-layered T1D progression model
- Multi-omics to link metabolism and epigenetics
- Multi-omics flux balance analysis
- MAMBA: Introducing multi-omics FBA
- Heat-shock response in yeast in mip6 mutant
- MAMBA improves metabolic prediction
- Metabolic regulation of heat-shock in yeast
- Key participation of trehalose in mip6 biology
- Acknowledgements
- Financial disclosures
Topics Covered
- Analysis of multi-omics data
- Sample size calculations in multi-omics
- STATegra dataset
- MORE: Multi-omics for gene local regulatory networks
- Bipartite regulatory network
- Modelling longitudinal multi-omics data
- Statistical modelling with NPLS-DA
- Paintomics
- Multi-omics flux balance analysis and MAMBA
Links
Series:
- Introduction to Computational Biology
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
Talk Citation
Conesa, A. (2025, December 31). Integration of multi-omics data [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 31, 2025, from https://doi.org/10.69645/YUXZ2713.Export Citation (RIS)
Publication History
- Published on December 31, 2025
Financial Disclosures
- There are no commercial/financial matters to disclose.
A selection of talks on Cardiovascular & Metabolic
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is Ana Conesa.
I'm a research professor
at the Spanish National
Research Council,
working at the Institute for
Integrative Systems Biology
in Valencia.
I will be talking to you
about the methods and
the strategies
developed in my lab
for the integration
of multi-omics data.
0:24
The analysis of multi-omics
data, as you may know,
is about the integration of
different types of
molecular information
that are represented
in different layers
that go from the genomics
data, epigenomics data,
gene expression
transcriptomics, proteomics,
metabolomics, and
even other types of
biological data like
single-cell of radiomics data.
We see this problem
as a situation
in which we could have
two different approaches
to do the integration.
One approach is that
you concentrate on the
samples, on the observations,
and you try to use
these molecular data
to cluster samples in a way
that we can identify
different subgroups.
In this scenario, once you
have identified the subgroups,
you can predict to which of them
an additional external
sample will belong.
The other approach is to
concentrate on the features.
So evaluate the
features that are
measured across the
different samples
and use them to infer
connections or
relationships between them,
leading to
multi-layered networks.
In this situation,
we can have two
different conditions,
and because of the
data identified,
particular components,
particular features
change their connectivity
between these two conditions.
In both cases, you may
have biomarkers that are
either definitory of the
clustering solution,
or they are hubs,
so they are important
components,
in this multi-layered network.
My lab is mostly interested
in this second scenario,
in which we are
looking at features,
and we are trying to understand
what the relationship
is between them.